Idiopathic Restless Legs SyndromePhase 3RLSNCT00806026
Long Term Study Of Pregabalin In Idiopathic Restless Legs Syndrome Patients
A Phase 3 study testing pramipexol and Pregabalin in people with Idiopathic Restless Legs Syndrome, run by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. at 110 sites in 9 countries.
Trial summary
This purpose of this study is to investigate the efficacy and tolerability of pregabalin in treating idiopathic RLS patients for up to 12 months. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Idiopathic Restless Legs Syndrome
- What is being tested?
- pramipexol and Pregabalin
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 731 participants
- Where
- 110 sitesin 9 countries
- Study dates
- Dec 2008to May 2011
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- idiopathic RLS with the presence of all four clinical manifestations of RLS
- RLS symptoms occur predominantly in the evening
- RLS history at least 6 months
- IRLS => 15 at the beginning and the end of placebo run-in
- Have =>15 nights with RLS symptoms in the month prior to screening
Who cannot join
- Any secondary RLS
- Current augmentation due to RLS treatment
- Placebo responders identified during the placebo run-in
Trial locations and contacts
110 sites in 9 countries.
110 sites in 9 countries
United States42 sites
Pfizer Investigational Site
Atlanta, Georgia, 30342
Pfizer Investigational Site
Aurora, Colorado, 80012
Pfizer Investigational Site
Austin, Texas, 78731
Pfizer Investigational Site
Baton Rouge, Louisiana, 70808
Pfizer Investigational Site
Birmingham, Alabama, 35209
Pfizer Investigational Site
Boca Raton, Florida, 33486
Pfizer Investigational Site
Chevy Chase, Maryland, 20815
Pfizer Investigational Site
Cincinnati, Ohio, 45219
Pfizer Investigational Site
Columbus, Ohio, 43210
Pfizer Investigational Site
Dallas, Texas, 75231
Pfizer Investigational Site
Glendale, Arizona, 85308
Pfizer Investigational Site
Hallandale, Florida, 33009
Pfizer Investigational Site
Houston, Texas, 77063
Pfizer Investigational Site
Jasper, Alabama, 35501
Pfizer Investigational Site
Lafayette Hill, Pennsylvania, 19444
Pfizer Investigational Site
Little Rock, Arkansas, 72205
Pfizer Investigational Site
Little Rock, Arkansas, 72211
Pfizer Investigational Site
Louisville, Kentucky, 40217
Pfizer Investigational Site
Miami, Florida, 33143
Pfizer Investigational Site
Minneapolis, Minnesota, 55415
Pfizer Investigational Site
New York, New York, 10019
Pfizer Investigational Site
Newton, Massachusetts, 02459
Pfizer Investigational Site
Northridge, California, 91325
Pfizer Investigational Site
Oklahoma City, Oklahoma, 73112
Pfizer Investigational Site
Overland Park, Kansas, 66212
Pfizer Investigational Site
Pembroke Pines, Florida, 33026
Pfizer Investigational Site
Phoenix, Arizona, 85032
Pfizer Investigational Site
Phoenix, Arizona, 85050
Pfizer Investigational Site
Plano, Texas, 75093
Pfizer Investigational Site
Princeton, New Jersey, 08540
Pfizer Investigational Site
Redondo Beach, California, 90277
Pfizer Investigational Site
Salisbury, North Carolina, 28144-0000
Pfizer Investigational Site
Salisbury, North Carolina, 28144
Pfizer Investigational Site
San Diego, California, 92103
Pfizer Investigational Site
San Diego, California, 92121
Pfizer Investigational Site
Santa Monica, California, 90404
Pfizer Investigational Site
South Miami, Florida, 33143
Pfizer Investigational Site
Southfield, Michigan, 48034
Pfizer Investigational Site
Torrance, California, 90502
Pfizer Investigational Site
Tuscaloosa, Alabama, 35406
Pfizer Investigational Site
Walla Walla, Washington, 99362
Pfizer Investigational Site
Winston-Salem, North Carolina, 27103
Germany37 sites
Pfizer Investigational Site
Achim, 28832
Pfizer Investigational Site
Bad Saarow, 15526
Pfizer Investigational Site
Berlin, 10117
Pfizer Investigational Site
Berlin, 10245
Pfizer Investigational Site
Berlin, 10365
Pfizer Investigational Site
Berlin, 10437
Pfizer Investigational Site
Berlin, 10629
Pfizer Investigational Site
Berlin, 10969
Pfizer Investigational Site
Berlin, 12163
Pfizer Investigational Site
Berlin, 12683
Pfizer Investigational Site
Berlin, 13156
Pfizer Investigational Site
Bochum, 44787
Pfizer Investigational Site
Bochum, 44805
Pfizer Investigational Site
Bremen, 28325
Pfizer Investigational Site
Dortmund, 44229
Pfizer Investigational Site
Dresden, 01307
Pfizer Investigational Site
Freiburg im Breisgau, 79106
Pfizer Investigational Site
Gelsenkirchen, 45879
Pfizer Investigational Site
Halle, 06118
Pfizer Investigational Site
Hamm, 59065
Pfizer Investigational Site
Jena, 07743
Pfizer Investigational Site
Jülich, 52428
Pfizer Investigational Site
Kassel, 34128
Pfizer Investigational Site
Kassel, 34131
Pfizer Investigational Site
Köthen, 06366
Pfizer Investigational Site
Leipzig, 04107
Pfizer Investigational Site
Marburg, 35039
Pfizer Investigational Site
München, 80331
Pfizer Investigational Site
Oldenburg, 26122
Pfizer Investigational Site
Prien am Chiemsee, 83209
Pfizer Investigational Site
Schwerin, 19053
Pfizer Investigational Site
Siegen, 57072
Pfizer Investigational Site
Ulm, 89073
Pfizer Investigational Site
Ulm, 89081
Pfizer Investigational Site
Unterhaching, 82008
Pfizer Investigational Site
Westerstede, 26655
Pfizer Investigational Site
Würzburg, 97070
Sweden10 sites
Pfizer Investigational Site
Avesta, 77482
Pfizer Investigational Site
Avesta, SE-774 82
Pfizer Investigational Site
Gothenburg, 40530
Pfizer Investigational Site
Gothenburg, 413 45
Pfizer Investigational Site
Örebro, 701 85
Pfizer Investigational Site
Örebro, 70185
Pfizer Investigational Site
Skövde, 541 85
Pfizer Investigational Site
Skövde, 54185
Pfizer Investigational Site
Skövde, SE-541 85
Pfizer Investigational Site
Stockholm, 11245
Italy6 sites
Pfizer Investigational Site
Pavia, 27100
Pfizer Investigational Site
Pisa, 56126
Pfizer Investigational Site
Rome, 00163
Pfizer Investigational Site
Rome, 00185
Pfizer Investigational Site
Troina, 94018
Pfizer Investigational Site
Troina(EN), 94018
Spain5 sites
Pfizer Investigational Site
Barcelona, Cataluña/Spain, 08003
Pfizer Investigational Site
Barcelona, 08035
Pfizer Investigational Site
Barcelona, 08036
Pfizer Investigational Site
Granada, 18014
Pfizer Investigational Site
Madrid, 28036
Finland4 sites
Pfizer Investigational Site
Helsinki, 00420
Pfizer Investigational Site
Kuopio, 70210
Pfizer Investigational Site
Tampere, 33520
Pfizer Investigational Site
Turku, 20520
Austria3 sites
Pfizer Investigational Site
Innsbruck, A-6020
Pfizer Investigational Site
Linz, A-4021
Pfizer Investigational Site
Vienna, 1090
Netherlands2 sites
Pfizer Investigational Site
Ede, 6716 RP
Pfizer Investigational Site
Zwolle, 8025 BV
United Kingdom1 site
Pfizer Investigational Site
Reading Berks, RG2 0TG
About this study
Official title: Randomized, Double Blind, 12-Month Study Of Pregabalin In Subjects With Restless Legs Syndrome
This purpose of this study is to investigate the efficacy and tolerability of pregabalin in treating idiopathic RLS patients for up to 12 months.
- Conditions
- Idiopathic Restless Legs Syndrome
- Being tested
- placebo and pregabalin, pramipexol, Pregabalin
- Keywords
- RLS
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
placebo and pregabalinDrug
Also called Lyrica
following 3 months placebo treatment, subjects are to be re-distributed to pregabalin 300 mg per day for 9 months. Both placebo and pregabalin are to be administered orally once a day, 1-3 hours before bedtime.
pramipexolDrug
Also called Mirapex
following 3 months placebo treatment, subjects are to be re-distributed to pramipexol 0.25mg per day for 9 months. Both placebo and pramipexol are to be administered orally once a day, 1-3 hours before bedtime.
pramipexolDrug
Also called Mirapex
following 3 months placebo treatment, subjects are to be re-distributed to pramipexol 0.5mg per day for 9 months. Both placebo and pramipexol are to be administered orally once a day, 1-3 hours before bedtime.
PregabalinDrug
Also called Lyrica
pregabalin 300 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
pramipexolDrug
Also called Mirapex
pramipexol 0.25 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
pramipexolDrug
Also called Mirapex
pramipexol 0.5 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
| Study group | Role | What they receive |
|---|---|---|
| PBO/PGB 300 mg | Experimental | Not described Receives: Drug: placebo and pregabalin |
| PBO/PPX 0.25 mg | Active comparator | Not described Receives: Drug: pramipexol |
| PBO/PPX 0.5 mg | Active comparator | Not described Receives: Drug: pramipexol |
| PGB 300 mg | Experimental | Not described Receives: Drug: Pregabalin |
| PPX 0.25 mg | Active comparator | Not described Receives: Drug: pramipexol |
| PPX 0.5 mg | Active comparator | Not described Receives: Drug: pramipexol |
What is being measured
The primary outcome is the main question the study is designed to answer.
Restless Legs Syndrome (RLS) Symptom Severity
International Restless Legs Syndrome Study Group Rating Scale (IRLS) is psychometrically and clinically valid and reliable clinician-administered instrument used to assess the severity of RLS. It assesses RLS symptom severity and impact on daily living and is comprised of 10 items, scored on 0 to 4 scale, where lower score indicates lower symptom severity/impact on living. Two subscale scores are symptom severity (6 items) ranging from 0-24 (lower score indicates lower symptom severity) and impact on daily living (3 items) ranging from 0-12 (lower score indicates lower impact on living). Item 3 is unrelated to the other items. The global score is calculated from all 10 items, range from 0 to 40, where lower scores reflect lower severity and better quality of life.
Measured: Baseline
Change From Baseline in the RLS Symptom Severity at Week 12
IRLS is psychometrically and clinically valid and reliable clinician-administered instrument used to assess the severity of RLS. It assesses RLS symptom severity and impact on daily living and is comprised of 10 items, scored on 0 to 4 scale, where lower score indicates lower symptom severity/impact on living. Two subscale scores are symptom severity (6 items) ranging from 0-24 (lower score indicates lower symptom severity) and impact on daily living (3 items) ranging from 0-12 (lower score indicates lower impact on living). Item 3 is unrelated to the other items. The global score is calculated from all 10 items, range from 0 to 40, where lower scores reflect lower severity and better quality of life.
Measured: Baseline, Week 12
Percentage of Participants Responding to Treatment at Week 12
CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected. Responders were defined as participants who report CGI-I score of "very much improved" or "much improved".
Measured: Week 12
Percentage of Participants With Augmentation
Augmentation was worsening of RLS symptoms, attributable to a specific long-term therapeutic intervention for RLS. Percentage of participants with augmentation was evaluated by centralized evaluation board using a set of assessment criteria for potential augmentation which included structured interview for diagnosis of augmentation during RLS treatment (SIDA-RLS), augmentation severity rating scale (ASRS), clinical judgment. ASRS measures severity of augmentation and consist of three items to be completed by clinician. Clinician would score participants' answers by comparing post-baseline evaluations to those at baseline. ASRS total score range: 0-24, with higher score indicating more severe augmentation.
Measured: Baseline up to Week 52
Secondary outcomes (18)
Subjective Sleep Questionnaire (SSQ): Subjective Waking After Sleep Onset (WASO)
SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). WASO is time spent awake from sleep onset to final awakening. Total WASO subscale (in minutes): numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Total WASO subscale score ranges from 0-1440 minutes. Lower value indicates better sleep.
Measured: Baseline
Change From Baseline in SSQ: Subjective WASO at Week 12
SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). WASO is time spent awake from sleep onset to final awakening. Total WASO subscale (in minutes): numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Total WASO subscale score ranges from 0-1440 minutes. Lower value indicates better sleep.
Measured: Baseline, Week 12
Subjective Sleep Questionnaire (SSQ): Latency Subscale Score at Week 12
SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). Latency subscale (in minutes): numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Latency subscale score ranges from 0-840 minutes. Lower value indicates better sleep.
Measured: Week 12
Subjective Sleep Questionnaire (SSQ): Hours of Sleep Subscale Score at Week 12
SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). Hours of sleep subscale: numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Hours of sleep subscale score ranges from 0-16 hours. Higher value indicates better sleep.
Measured: Week 12
Subjective Sleep Questionnaire (SSQ): Number of Awakenings Subscale Score at Week 12
SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). Number of awakenings subscale: numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Number of awakenings subscale score ranges from 0-30. Lower value indicates better sleep.
Measured: Week 12
Subjective Sleep Questionnaire (SSQ): Quality of Sleep Subscale Score at Week 12
SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). Quality of sleep subscale: numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Quality of sleep subscale score ranges from 0-100. Higher score indicates better quality of sleep.
Measured: Week 12
RLS-Next Day Impact (RLS-NDI)
The RLS-NDI is a participant-rated instrument designed to assess daytime performance as related to RLS and the participant's previous night's sleep. The instrument consists of 14 items that encompass 5 domains: tiredness; emotional functioning; social functioning; cognitive functioning; and activities of daily living. There is also 1 global item assessing overall well -being. Each item is scored on a 0-10 numeric rating scale. Total score is the sum of scores from question 1 to 14. The total score ranges from 0 to 140 where higher scores indicate a more severe impact.
Measured: Baseline
Change From Baseline in RLS-NDI at Week 12
The RLS-NDI is a participant-rated instrument designed to assess daytime performance as related to RLS and the participant's previous night's sleep. The instrument consists of 14 items that encompass 5 domains: tiredness; emotional functioning; social functioning; cognitive functioning; and activities of daily living. There is also 1 global item assessing overall well -being. Each item is scored on a 0-10 numeric rating scale. Total score is the sum of scores from question 1 to 14. The total score ranges from 0 to 140 where higher scores indicate a more severe impact.
Measured: Baseline, Week 12
Limb Pain-Visual Analog Scale (Limb Pain-VAS)
100 millimeter (mm) line (Visual Analog Scale) marked by participant. Intensity of pain range (over past week): 0 mm = no pain to 100 mm = worst possible pain.
Measured: Baseline
Change From Baseline in Limb Pain-VAS at Week 12
100 mm line (VAS) marked by participant. Intensity of pain range (over past week): 0 mm = no pain to 100 mm = worst possible pain. Change = observation mean minus baseline mean.
Measured: Baseline, Week 12
Severity of Augmentation Symptoms at Week 12
ASRS measures severity of augmentation and consist of three items to be completed by clinician. Clinician would score participants' answers by comparing post-baseline evaluations to those at baseline. ASRS total score range: 0-24, with higher score indicating more severe augmentation.
Measured: Week 12
Clinical Global Impressions-Severity (CGI-S) at Week 12
CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal-not ill at all) to 7 (among the most extremely ill participants). Higher score = more affected.
Measured: Week 12
Medical Outcomes Study-Sleep Scale (MOS-SS) at Week 12
MOS-SS: Participant rated instrument to assess sleep quantity, quality; comprised of 12 items yielding 7 subscale scores: sleep disturbance, snoring, awakening short of breath/headache, sleep adequacy, somnolence, sleep quantity, optimal sleep, 2 composite index scores: sleep problems Index I, II. Sleep adequacy data was reported at week 12 and not for first 12 weeks (average). Subscale scores range: 0-100; exception quantity of sleep (range 0-24 hours). With exception of sleep quantity and sleep adequacy, higher scores reflect poorer sleep outcomes.
Measured: Week 12
Number of Participants With Medical Outcomes Study-Sleep Scale (MOS-SS)- Optimal Sleep at Week 12
MOS-SS: Participant rated instrument to assess sleep quantity, quality; comprised of 12 items yielding 7 subscale scores: sleep disturbance, snoring, awakening short of breath/ headache, sleep adequacy, somnolence, sleep quantity, optimal sleep, 2 composite index scores: sleep problems Index I, II. Optimal sleep subscale scores range: 0-1; Optimal sleep = 1 if 'Average hours sleep' = 7 or 8, is 0 if 'Average hours sleep' is non-missing and less than 7, and is missing if 'Average hours sleep' is missing. Higher scores reflect better sleep outcomes.
Measured: Week 12
Profile of Mood State (POMS) at Week 12
POMS are participant-rated instrument comprising 6 sub-scales (tension-anxiety, depression-dejection, anger-hostility, vigor-activity, fatigue-inertia, and confusion-bewilderment) and each subscale comprising 5 items, on 'How you feel right now?' (Scale: 0=not at all, 1=a little, 2=moderately, 3=quite a bit, 4=extremely). All items were rated in the same direction except for vigor-activity. A total score is obtained for each scale. The range of total score is 0 - 100, with higher score indicating more mood disturbance.
Measured: Week 12
Restless Legs Syndrome-Quality of Life Scale (RLS-QoL) at Week 12
RLS QoL: Participant rated instrument used to assess the impact of RLS on quality of life and health status function (symptom severity, daily activity, social functioning, sleep, concentrating and decision making, traveling, sexual activity, and work) yielding a summary score ranging from 0-100. Higher scores reflect better quality of life.
Measured: Week 12
Medical Outcomes Study-Short Form 36 (SF-36) at Week 12
SF-36 is a standardized survey evaluating 8 aspects of functional health and well being (physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health); 2 summary scores (physical and mental component); and self evaluated change in health status (summary of health status). The score for subscale scores and 2 summary score is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Summary of health status is a 5-point Likert scale ranging from "0=much worse now" to "4=much better now". Higher subscale and summary score reflect better health status.
Measured: Week 12
Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP) at Week 12
WPAI: 6 question participant rated questionnaire to determine degree to which SHP affected work productivity while at work and outside of work. Four scores are derived: percentage of absenteeism and presenteeism (reduced productivity while at work), overall work impairment score combining absenteeism and presenteeism, percentage of impairment in activities performed outside of work. Score range: 0 (not affected/no impairment) to 10 (completely affected/impaired). WPAI outcomes expressed as impairment percentages with higher numbers indicating greater impairment and less productivity.
Measured: Week 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Dec 2008 (estimated)
- Study startDec 2008
- Primary completionMay 2011
- Study completionMay 2011
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Idiopathic Restless Legs SyndromeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 731 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00806026
- Sponsor's protocol ID
- A0081186
- Acronym
- RLS
- Status last verified
- Aug 2012
- First submitted
- 9 Dec 2008
- Last updated
- 26 Jan 2021
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
Allen RP, Chen C, Garcia-Borreguero D, Polo O, DuBrava S, Miceli J, Knapp L, Winkelman JW. Comparison of pregabalin with pramipexole for restless legs syndrome. N Engl J Med. 2014 Feb 13;370(7):621-31. doi: 10.1056/NEJMoa1303646.
PubMed 24521108
Study at a glance
From the registry record, last updated by the sponsor on 26 Jan 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomized, Double Blind, 12-Month Study Of Pregabalin In Subjects With Restless Legs Syndrome
- ClinicalTrials.gov ID
- NCT00806026
- Acronym / sponsor ID
- RLS / A0081186
- Conditions
- Idiopathic Restless Legs Syndrome
- Keywords
- RLS
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 731 participants (actual)
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Industry (pharma, biotech, devices)
- Study start
- Dec 2008
- Primary completion
- May 2011 (actual)
- Study completion
- May 2011 (actual)
- First posted
- 10 Dec 2008 (estimated)
- Results
- Posted 27 Sep 2012
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This purpose of this study is to investigate the efficacy and tolerability of pregabalin in treating idiopathic RLS patients for up to 12 months.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 6
| Arm | Type | Receives |
|---|---|---|
| PBO/PGB 300 mg | Experimental | Drug: placebo and pregabalin |
| PBO/PPX 0.25 mg | Active comparator | Drug: pramipexol |
| PBO/PPX 0.5 mg | Active comparator | Drug: pramipexol |
| PGB 300 mg | Experimental | Drug: Pregabalin |
| PPX 0.25 mg | Active comparator | Drug: pramipexol |
| PPX 0.5 mg | Active comparator | Drug: pramipexol |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- idiopathic RLS with the presence of all four clinical manifestations of RLS
- RLS symptoms occur predominantly in the evening
- RLS history at least 6 months
- IRLS => 15 at the beginning and the end of placebo run-in
- Have =>15 nights with RLS symptoms in the month prior to screening
Key exclusion criteria (3 listed)
- Any secondary RLS
- Current augmentation due to RLS treatment
- Placebo responders identified during the placebo run-in
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| placebo and pregabalinAlso: Lyricafollowing 3 months placebo treatment, subjects are to be re-distributed to pregabalin 300 mg per day for 9 months. Both placebo and pregabalin are to be administered orally once a day, 1-3 hours before bedtime. | Drug | PBO/PGB 300 mg |
| pramipexolAlso: Mirapexfollowing 3 months placebo treatment, subjects are to be re-distributed to pramipexol 0.25mg per day for 9 months. Both placebo and pramipexol are to be administered orally once a day, 1-3 hours before bedtime. | Drug | PBO/PPX 0.25 mg |
| pramipexolAlso: Mirapexfollowing 3 months placebo treatment, subjects are to be re-distributed to pramipexol 0.5mg per day for 9 months. Both placebo and pramipexol are to be administered orally once a day, 1-3 hours before bedtime. | Drug | PBO/PPX 0.5 mg |
| PregabalinAlso: Lyricapregabalin 300 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months | Drug | PGB 300 mg |
| pramipexolAlso: Mirapexpramipexol 0.25 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months | Drug | PPX 0.25 mg |
| pramipexolAlso: Mirapexpramipexol 0.5 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months | Drug | PPX 0.5 mg |
Primary outcome
Restless Legs Syndrome (RLS) Symptom Severity
Time frame: Baseline
International Restless Legs Syndrome Study Group Rating Scale (IRLS) is psychometrically and clinically valid and reliable clinician-administered instrument used to assess the severity of RLS. It assesses RLS symptom severity and impact on daily living and is comprised of 10 items, scored on 0 to 4 scale, where lower score indicates lower symptom severity/impact on living. Two subscale scores are symptom severity (6 items) ranging from 0-24 (lower score indicates lower symptom severity) and impact on daily living (3 items) ranging from 0-12 (lower score indicates lower impact on living). Item 3 is unrelated to the other items. The global score is calculated from all 10 items, range from 0 to 40, where lower scores reflect lower severity and better quality of life.
Change From Baseline in the RLS Symptom Severity at Week 12
Time frame: Baseline, Week 12
IRLS is psychometrically and clinically valid and reliable clinician-administered instrument used to assess the severity of RLS. It assesses RLS symptom severity and impact on daily living and is comprised of 10 items, scored on 0 to 4 scale, where lower score indicates lower symptom severity/impact on living. Two subscale scores are symptom severity (6 items) ranging from 0-24 (lower score indicates lower symptom severity) and impact on daily living (3 items) ranging from 0-12 (lower score indicates lower impact on living). Item 3 is unrelated to the other items. The global score is calculated from all 10 items, range from 0 to 40, where lower scores reflect lower severity and better quality of life.
Percentage of Participants Responding to Treatment at Week 12
Time frame: Week 12
CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected. Responders were defined as participants who report CGI-I score of "very much improved" or "much improved".
Percentage of Participants With Augmentation
Time frame: Baseline up to Week 52
Augmentation was worsening of RLS symptoms, attributable to a specific long-term therapeutic intervention for RLS. Percentage of participants with augmentation was evaluated by centralized evaluation board using a set of assessment criteria for potential augmentation which included structured interview for diagnosis of augmentation during RLS treatment (SIDA-RLS), augmentation severity rating scale (ASRS), clinical judgment. ASRS measures severity of augmentation and consist of three items to be completed by clinician. Clinician would score participants' answers by comparing post-baseline evaluations to those at baseline. ASRS total score range: 0-24, with higher score indicating more severe augmentation.
18 secondary outcomes
Subjective Sleep Questionnaire (SSQ): Subjective Waking After Sleep Onset (WASO)
Time frame: Baseline
Change From Baseline in SSQ: Subjective WASO at Week 12
Time frame: Baseline, Week 12
Subjective Sleep Questionnaire (SSQ): Latency Subscale Score at Week 12
Time frame: Week 12
Subjective Sleep Questionnaire (SSQ): Hours of Sleep Subscale Score at Week 12
Time frame: Week 12
Subjective Sleep Questionnaire (SSQ): Number of Awakenings Subscale Score at Week 12
Time frame: Week 12
Subjective Sleep Questionnaire (SSQ): Quality of Sleep Subscale Score at Week 12
Time frame: Week 12
RLS-Next Day Impact (RLS-NDI)
Time frame: Baseline
Change From Baseline in RLS-NDI at Week 12
Time frame: Baseline, Week 12
Limb Pain-Visual Analog Scale (Limb Pain-VAS)
Time frame: Baseline
Change From Baseline in Limb Pain-VAS at Week 12
Time frame: Baseline, Week 12
Severity of Augmentation Symptoms at Week 12
Time frame: Week 12
Clinical Global Impressions-Severity (CGI-S) at Week 12
Time frame: Week 12
Medical Outcomes Study-Sleep Scale (MOS-SS) at Week 12
Time frame: Week 12
Number of Participants With Medical Outcomes Study-Sleep Scale (MOS-SS)- Optimal Sleep at Week 12
Time frame: Week 12
Profile of Mood State (POMS) at Week 12
Time frame: Week 12
Restless Legs Syndrome-Quality of Life Scale (RLS-QoL) at Week 12
Time frame: Week 12
Medical Outcomes Study-Short Form 36 (SF-36) at Week 12
Time frame: Week 12
Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP) at Week 12
Time frame: Week 12
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Jan 2021.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 24521108Allen RP, Chen C, Garcia-Borreguero D, Polo O, DuBrava S, Miceli J, Knapp L, Winkelman JW. Comparison of pregabalin with pramipexole for restless legs syndrome. N Engl J Med. 2014 Feb 13;370(7):621-31. doi: 10.1056/NEJMoa1303646.
- To obtain contact information for a study center near you, click here.Link provided by the sponsor.
Related trials for Idiopathic Restless Legs Syndrome
Not yet recruitingPhase 2
Tolerability and Efficacy of CBD Extract for RLS Treatment
Restless Leg Syndrome
RecruitingObservational study
Mainz Register of Patients With Sleep Disorders
Sleep Disorder, Sleep Disorder Parasomnia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pfizer CT.gov Call Center study director
Pfizer
110 sites in 9 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing pramipexol and Pregabalin in people with Idiopathic Restless Legs Syndrome, run by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. at 110 sites in 9 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 26 Jan 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 110 sites in United States, Germany, Sweden, Italy, Spain and 4 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 27 Sep 2012). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Restless Legs Syndrome (RLS) Symptom Severity (time frame: Baseline). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00806026, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jan 2021.